This segment focuses on the development and commercialization of treatments for opioid and other substance use disorders, as well as overdose reversal medications. Key products include NARCAN® Nasal Spray, a widely used opioid overdose reversal medication. Research and development efforts are directed towards novel formulations and delivery methods for existing drugs, as well as the discovery of new chemical entities with potential for treating addiction. The segment addresses the critical need for effective interventions in the face of the ongoing opioid crisis, aiming to reduce overdose fatalities and improve patient outcomes. Future opportunities include expanding the reach of NARCAN® and developing new treatments for emerging drug threats, such as synthetic cannabinoids. Regulatory compliance and clinical validation are essential aspects of this segment, ensuring the safety and efficacy of its products.